Buserelin: What the Research Says: Benefits, Risks, and Protocols
Medically reviewed by Dr. Sarah Chen, PharmD, BCPS
A research-based overview of Buserelin, a GnRH agonist used in the treatment of prostate cancer, endometriosis, and in assisted reproductive technologies, covering its benefits, risks, and treatment protocols.
Buserelin: A Versatile GnRH Agonist in Modern Medicine
Buserelin is a potent synthetic gonadotropin-releasing hormone (GnRH) agonist that has been a mainstay in the treatment of various hormone-dependent conditions for decades. By manipulating the body's production of sex hormones, Buserelin offers therapeutic benefits in a range of applications, from cancer treatment to assisted reproduction. It is available in various formulations, including a nasal spray and a subcutaneous implant.
Mechanism of Action: The Power of Downregulation
Like other GnRH agonists, Buserelin works through a process of pituitary desensitization. Initially, it stimulates the pituitary gland to release a surge of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). However, with continuous administration, the pituitary becomes desensitized to GnRH, leading to a profound suppression of LH and FSH secretion. This, in turn, shuts down the production of testosterone in men and estrogen in women, a state often referred to as "medical castration." This reversible suppression of sex hormones is the cornerstone of Buserelin's therapeutic effects.
Benefits and Clinical Applications
Buserelin has a wide range of clinical applications, including:
Prostate Cancer: In men with advanced prostate cancer, Buserelin is used to reduce testosterone levels, which can slow the growth and spread of the tumor. It is a standard of care in the hormonal therapy of prostate cancer.
Endometriosis: By suppressing estrogen production, Buserelin helps to alleviate the pain and other symptoms of endometriosis.
Assisted Reproductive Technology (ART): In IVF cycles, Buserelin is used to prevent premature ovulation, allowing for the controlled maturation and retrieval of multiple eggs.
Central Precocious Puberty: Buserelin can be used to halt the early onset of puberty in children.
| Application | Benefit of Buserelin |
| :--- | :--- |
| Prostate Cancer | Reduces testosterone, slows tumor growth |
| Endometriosis | Suppresses estrogen, reduces pain |
| IVF | Prevents premature ovulation, improves egg retrieval |
| Central Precocious Puberty | Halts early pubertal development |
Risks and Side Effects
The side effects of Buserelin are primarily a consequence of the low sex hormone levels it induces. Common side effects include:
Hot flashes
Decreased libido
Erectile dysfunction (in men)
Vaginal dryness (in women)
Bone density loss (with long-term use)
An initial "flare-up" of symptoms can occur at the beginning of treatment, particularly in men with prostate cancer, which may require the co-administration of an anti-androgen.
Treatment Protocols
The treatment protocol for Buserelin varies depending on the condition being treated and the formulation used. For prostate cancer, it is often administered as a long-acting subcutaneous implant. For IVF, it is typically given as a daily subcutaneous injection or nasal spray. The duration of treatment also varies, from a few weeks in an IVF cycle to many years for prostate cancer.
Key Takeaways
Buserelin is a GnRH agonist that suppresses the production of testosterone and estrogen.
It is used to treat prostate cancer, endometriosis, and in assisted reproductive technologies.
Side effects are related to low sex hormone levels and include hot flashes and decreased libido.
Treatment protocols vary depending on the condition and formulation.
> Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any peptide therapy or making changes to your health regimen.
References
[1] Brogden, R. N., & Buckley, M. M. (1990). Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile. Drugs, 39(3), 399–437. https://link.springer.com/article/10.2165/00003495-199039030-00007
[2] Kienle, E., & Lübben, G. (1989). Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). The New England journal of medicine*, 321(7), 413–417. https://www.nejm.org/doi/full/10.1056/NEJM198908173210701
[3] Buserelin. (2012). BC Cancer. https://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Buserelin_monograph_1March2012.pdf
---